---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-147583"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:57:26.097970+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval

## Summary
- Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).
- Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.
- Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.
- Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.
- Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions.

## SEC filing metadata
- accession: 0001193125-24-147583
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/0001193125-24-147583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/d717537d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-147583
- JSON: https://secwatch.observer/filing/0001193125-24-147583.json
- Plain text: https://secwatch.observer/filing/0001193125-24-147583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.